XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
36.21
-0.95 (-2.56%)
At close: Oct 8, 2025, 4:00 PM EDT
36.35
+0.14 (0.39%)
After-hours: Oct 8, 2025, 4:10 PM EDT
XOMA Royalty Revenue
XOMA Royalty had revenue of $13.13M in the quarter ending June 30, 2025, with 18.43% growth. This brings the company's revenue in the last twelve months to $44.95M, up 194.98% year-over-year. In the year 2024, XOMA Royalty had annual revenue of $28.49M with 498.72% growth.
Revenue (ttm)
$44.95M
Revenue Growth
+194.98%
P/S Ratio
9.61
Revenue / Employee
$3,457,846
Employees
13
Market Cap
437.70M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.49M | 23.73M | 498.72% |
Dec 31, 2023 | 4.76M | -1.27M | -21.06% |
Dec 31, 2022 | 6.03M | -32.13M | -84.21% |
Dec 31, 2021 | 38.16M | 8.78M | 29.86% |
Dec 31, 2020 | 29.39M | 11.02M | 59.96% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
XOMA News
- 5 days ago - XOMA Royalty PFD Update: Going Back To My Original Sell Ratings - Seeking Alpha
- 6 days ago - XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - GlobeNewsWire
- 14 days ago - ESSA Pharma Inc. Amends Agreement with XenoTherapeutics - PRNewsWire
- 16 days ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire
- 21 days ago - XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. - GlobeNewsWire
- 5 weeks ago - XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 7 weeks ago - Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share - GlobeNewsWire
- 2 months ago - XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewsWire